Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/psc.2858 http://scihub22266oqcxt.onion/10.1002/psc.2858 C4883657!4883657 !26880702     free     free     free Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26880702 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Pept+Sci 2016 ; 22 (4 ): 196-200 Nephropedia Template TP {{tp|p=26880702 |t=2016. Degradation of Akt using protein-catalyzed capture agents |pdf=|usr=}}{{26880702 }} gab.com Text Degradation of Akt using protein-catalyzed capture agents JO: J Pept Sci http://www.kidney.de/pget.php?&tw=1&pmid=26880702 #FOAvip Abnormal signaling of the protein kinase Akt has been shown to contribute to human diseases such as diabetes and cancer, but Akt has proven to be a challenging target for drugging. Using iterative in situ click chemistry, we recently developed multiple protein-catalyzed capture (PCC) agents that allosterically modulate Akt enzymatic activity in a protein-based assay. Here, we utilize similar PCCs to exploit endogenous protein degradation pathways. We use the modularity of the anti-Akt PCCs to prepare proteolysis targeting chimeric molecules that are shown to promote the rapid degradation of Akt in live cancer cells. These novel proteolysis targeting chimeric molecules demonstrate that the epitope targeting selectivity of PCCs can be coupled with non-traditional drugging moieties to inhibit challenging targets. Twit Text FOAVip Degradation of Akt using protein-catalyzed capture agents ????J Pept Sci http://www.kidney.de/pget.php?&tw=1&pmid=26880702 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26880702 #FOAvip English Wikipedia <ref>{{Cite pmid|26880702 }}</ref> Degradation of Akt using protein-catalyzed capture agents #MMPMID26880702 Henning RK ; Varghese JO ; Das S ; Nag A ; Tang G ; Tang K ; Sutherland AM ; Heath JR J Pept Sci 2016[Apr]; 22 (4 ): 196-200 PMID26880702 show ga Abnormal signaling of the protein kinase Akt has been shown to contribute to human diseases such as diabetes and cancer, but Akt has proven to be a challenging target for drugging. Using iterative in situ click chemistry, we recently developed multiple protein-catalyzed capture (PCC) agents that allosterically modulate Akt enzymatic activity in a protein-based assay. Here, we utilize similar PCCs to exploit endogenous protein degradation pathways. We use the modularity of the anti-Akt PCCs to prepare proteolysis targeting chimeric molecules that are shown to promote the rapid degradation of Akt in live cancer cells. These novel proteolysis targeting chimeric molecules demonstrate that the epitope targeting selectivity of PCCs can be coupled with non-traditional drugging moieties to inhibit challenging targets. |Antineoplastic Agents/*pharmacology [MESH] |Catalysis [MESH] |Cell Line, Tumor [MESH] |Cell Proliferation [MESH] |Drug Screening Assays, Antitumor [MESH] |Enzyme Activation [MESH] |Humans [MESH] |Hypoxia-Inducible Factor 1, alpha Subunit/metabolism [MESH] |Inhibitory Concentration 50 [MESH] |Molecular Targeted Therapy [MESH] |Peptides/*pharmacology [MESH] |Proteolysis [MESH]Degradation of Akt using protein-catalyzed capture agents (epmc).pdf DeepDyve Pubget Overpricing